Analyst Price Targets — RHHBY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 6:52 am | Sarita Kapila | Morgan Stanley | $63.00 | $56.17 | StreetInsider | Morgan Stanley Upgrades Roche (RHHBY) to Overweight |
| December 10, 2025 11:17 am | — | HSBC | $57.00 | $48.66 | TheFly | Roche price target raised to $57 from $50 at HSBC |
| October 2, 2025 9:07 am | Rajesh Kumar | HSBC | $50.00 | $44.83 | TheFly | Roche upgraded to Buy from Hold at HSBC (yesterday) |
| June 27, 2022 8:11 am | — | Cowen & Co. | $48.00 | $41.64 | Benzinga | Cowen & Co. Maintains Outperform on Roche Holding, Lowers Price Target to $48 |
Latest News for RHHBY
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
David Roche of Quantum Strategy says oil flows out of the Strait of Hormuz are likely to be far lower than what the U.S. claims. He adds that while Washington's economic pressure on Tehran is growing, it's unlikely to change Iran's strategy of wanting to control the Strait of Hormuz.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY HER2 (4B5) and VENTANA
They aren't the most prominent names in the GLP-1 space, but they are worth a second look.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RHHBY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.